DexCom (NASDAQ:DXCM) EVP Sells 2,565 Shares of Company Stock

Key Points

• DexCom EVP Sadie Stern sold 2,565 shares at an average price of $78.62, generating approximately $201,660. The transaction was made under a pre-arranged Rule 10b5-1 plan and reduced her holdings by 2.08% to 120,913 shares.
• DexCom shares were trading at $78.62, below their 50-day moving average of $86.18 but above their 200-day average of $74.54. The stock has a market capitalization of approximately $29.67 billion.
• Analysts maintain a generally positive outlook, with a consensus “Buy” rating and an average price target of $92.43. The company recently exceeded quarterly earnings and revenue estimates, reporting $0.70 EPS and $1.31 billion in revenue.

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) EVP Sadie Stern sold 2,565 shares of the company's stock in a transaction dated Tuesday, October 27th. The shares were sold at an average price of $78.62, for a total value of $201,660.30. Following the sale, the executive vice president owned 120,913 shares in the company, valued at approximately $9,506,180.06. This represents a 2.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sadie Stern also recently made the following trade(s):

• On Monday, September 28th, Sadie Stern sold 2,565 shares of DexCom stock. The stock was sold at an average price of $86.15, for a total transaction of $220,974.75.
• On Thursday, August 27th, Sadie Stern sold 2,565 shares of DexCom stock. The shares were sold at an average price of $88.37, for a total transaction of $226,669.05.

DexCom Price Performance

NASDAQ:DXCM traded up $0.06 during mid-day trading on Wednesday, hitting $78.62. 5,371,382 shares of the stock traded hands, compared to its average volume of 5,011,880. The business's 50-day moving average price is $86.18 and its 200 day moving average price is $74.54. The company has a market cap of $29.67 billion, a PE ratio of 31.08, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same quarter in the prior year, the firm posted $0.48 EPS. DexCom's revenue was up 13.1% on a year-over-year basis. On average, analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Hedge Funds Weigh In On DexCom

Hedge funds and other institutional investors have recently modified their holdings of the company. Plato Investment Management Ltd bought a new stake in DexCom in the 2nd quarter worth approximately $782,000. Aurora Investment Counsel purchased a new stake in DexCom in the second quarter worth approximately $2,340,000. E Fund Management Co. Ltd. purchased a new stake in DexCom in the second quarter worth approximately $1,273,000. Silvant Capital Management LLC purchased a new stake in DexCom in the second quarter worth approximately $5,359,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in DexCom during the second quarter valued at approximately $89,940,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Mizuho set a $100.00 price target on shares of DexCom in a report on Tuesday, October 13th. BTIG Research lifted their price objective on DexCom from $90.00 to $96.00 and gave the company a "buy" rating in a research note on Monday, October 12th. Raymond James Financial restated a "strong-buy" rating and set a $94.00 target price on shares of DexCom in a research report on Friday, July 31st. Royal Bank Of Canada restated an "outperform" rating and issued a $105.00 target price (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. raised their price target on DexCom from $65.00 to $82.00 and gave the company a "neutral" rating in a report on Friday, July 31st. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $92.43.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.